10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
10x Genomics (NASDAQ: TXG) launched the next generation of its Chromium Flex assay on October 29, 2025, introducing automation-compatible plate-based multiplexing to scale single cell studies.
The assay supports profiling up to 384 samples and 100 million cells per week in a 96-well plate format, claims improved sequencing efficiency and sensitivity from Flex chemistry, and aims to lower per-sample cost while reducing reagent waste. Early access customers at research institutes and pharma report faster throughput and compatibility with liquid-handling automation. New Flex is available globally and targets high-cell and high-sample applications such as CRISPR screens and FFPE translational studies.
10x Genomics (NASDAQ: TXG) ha lanciato la prossima generazione del suo saggio Chromium Flex il 29 ottobre 2025, introducendo un multiplexing basato su piastre compatibile con l'automazione per scalare gli studi su singola cellula.
Il saggio supporta l'analisi di fino a 384 campioni e 100 milioni di cellule a settimana, in una formattazione a piastre da 96 pozzetti, afferma una maggiore efficienza e sensibilità di sequenziamento rispetto alla chimica Flex, e mira a ridurre i costi per campione riducendo i rifiuti di reagenti. I clienti con accesso anticipato presso istituti di ricerca e aziende farmaceutiche riportano una maggiore velocità di throughput e compatibilità con l'automazione di gestione dei liquidi. New Flex è disponibile a livello globale e si propone per applicazioni con alto numero di cellule e di campioni, come gli schermi CRISPR e gli studi traslazionali FFPE.
10x Genomics (NASDAQ: TXG) lanzó la próxima generación de su ensayo Chromium Flex el 29 de octubre de 2025, introduciendo un multiplexado en placa compatible con automatización para escalar estudios de una sola célula.
El ensayo admite perfilar hasta 384 muestras y 100 millones de células por semana en un formato de placa de 96 pocillos, afirma mayor eficiencia y sensibilidad de secuenciación respecto a la química Flex, y busca reducir el costo por muestra al mismo tiempo que disminuye el desperdicio de reactivos. Clientes de acceso temprano en institutos de investigación y farmacéuticas reportan mayor rendimiento y compatibilidad con la automatización de manejo de líquidos. New Flex está disponible globalmente y se dirige a aplicaciones de alto consumo de células y muestras, como pantallas CRISPR y estudios traslacionales FFPE.
10x Genomics (NASDAQ: TXG)은 2025년 10월 29일 차세대 Chromium Flex 분석을 선보이며 자동화 호환 플레이트 기반 멀티플렉싱을 도입하여 단일 세포 연구를 확장했습니다.
해당 분석은 384개 샘플과 주당 최대 1억 개의 세포를 96웰 플레이트 형식으로 프로파일링할 수 있으며, Flex 화학에서의 시퀀싱 효율성과 민감도가 개선되었다고 주장하고, 시약 폐기물을 줄이면서 샘플당 비용을 낮추는 것을 목표로 합니다. 연구기관과 제약사에 속한 조기 접근 고객은 더 빠른 처리량과 액체 취급 자동화와의 호환성을 보고합니다. New Flex는 전 세계적으로 사용 가능하며 CRISPR 스크린 및 FFPE 트랜스레이셔널 연구와 같은 고세포/고샘플 응용 분야를 겨냥합니다.
10x Genomics (NASDAQ: TXG) a lancé la prochaine génération de son test Chromium Flex le 29 octobre 2025, en introduisant un multiplexage basé sur plaque compatible avec l'automatisation pour scaler les études à cellule unique.
Le test permet de profiler jusqu'à 384 échantillons et 100 millions de cellules par semaine dans un format de plaque à 96 puits, affirme une meilleure efficacité et sensibilité du séquençage grâce à la chimie Flex, et vise à réduire le coût par échantillon tout en diminuant les déchets de réactifs. Des clients en accès anticipé dans des instituts de recherche et dans l'industrie pharmaceutique signalent un débit plus rapide et une compatibilité avec l'automatisation de la manipulation des liquides. New Flex est disponible globalement et cible des applications à haut nombre de cellules et d'échantillons, telles que les écrans CRISPR et les études translationnelles FFPE.
10x Genomics (NASDAQ: TXG) hat die nächste Generation seines Chromium Flex-Tests am 29. Oktober 2025 eingeführt und eine automatisierungsfreundliche platesbasierte Multiplexing-Technik vorgestellt, um Einzelzellstudien zu skalieren.
Der Test unterstützt das Profiling von bis zu 384 Proben und 100 Millionen Zellen pro Woche in einem 96-Well-Plate-Format, behauptet eine verbesserte Sequenzierungseffizienz und Empfindlichkeit durch die Flex-Chemie und zielt darauf ab, die Kosten pro Probe zu senken, während Abfall von Reagenzien reduziert wird. Frühzugangskunden an Forschungsinstituten und in der Pharmaindustrie berichten von schnellerem Durchsatz und Kompatibilität mit liquid-handling-Automatisierung. New Flex ist global erhältlich und richtet sich an Anwendungen mit vielen Zellen und Proben wie CRISPR-Screens und FFPE-Translationsstudien.
10x Genomics (NASDAQ: TXG) أطلقت الجيل التالي من اختبار Chromium Flex في 29 أكتوبر 2025، مقدمة ضبطًا آليًا قائمًا على ألواح للمزج متعدد الأساليب لتوسيع الدراسات الخلوية المفردة.
يدعم الاختبار تحليل حتى 384 عينة و 100 مليون خلية في الأسبوع في صيغة لوحة 96-جُزء، ويدّعي كفاءة تسلسل وتحسسًا محسّنين من كيمياء Flex، ويهدف إلى خفض تكلفة العينة الواحدة مع تقليل مخلفات المحاليل. يورد عملاء الوصول المبكر في المعاهد البحثية وشركات الأدوية معدل إنتاجية أسرع وتوافقًا مع أتمتة التعامل مع السوائل. New Flex متاح عالميًا ويستهدف تطبيقات عالية الخلايا والعيّنات مثل فحوص CRISPR ودراسات FFPE الترجماتية.
10x Genomics (NASDAQ: TXG) 于 2025 年 10 月 29 日推出其 Chromium Flex 测试的下一代，引入与自动化兼容的板板式多重检测，以扩展单细胞研究。
该测试支持在 96 孔板格式下对多达 384 个样本 和 每周 1 亿个细胞进行分析，声称比 Flex 化学改进了测序效率和灵敏度，并旨在降低每样本成本，同时减少试剂浪费。处于早期准入的研究机构和制药公司客户报告出更快的通量和对液体处理自动化的兼容性。New Flex 全球可用，面向高细胞量和高样本量的应用，如 CRISPR 筛选和 FFPE 转化研究。
- 384-sample plate multiplexing capacity
- 100 million cells/week throughput on a 96-well workflow
- Built on proven Flex chemistry for sensitivity and sequencing efficiency
- Automation-compatible format enabling integration with liquid handlers
- Reduced reagent waste and lower per-sample cost
- None.
Insights
New automation-compatible, plate-based Flex boosts throughput to 384 samples and 100 million cells weekly, expanding single-cell scale and lowering per-sample cost.
10x Genomics expands its Flex assay into a plate-based, automation-compatible format that explicitly supports processing up to 384 samples and "100 million cells per week" in a 96-well workflow. The announcement states the assay keeps the existing Flex chemistry sensitivity and sequencing efficiency while enabling modular multiplexing, reagent savings, and compatibility with liquid-handling automation.
The business impact flows from two clear mechanics: materially higher sample and cell throughput, and lower per-experiment reagent waste and cost. These mechanics directly support high cell-count use cases such as CRISPR functional screens and high-sample FFPE translational cohorts, as stated, and already have early access users testing the workflow.
Key dependencies and risks include real-world integration with customers' automation systems and sustained data quality at scale; those factors determine adoption speed. Monitor early access performance metrics, reported throughput, and customer deployment case studies over the next 6-18 months starting from
New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies
With the new assay, researchers can now profile up to 384 samples and 100 million cells per week using a 96-well plate format that integrates seamlessly with 10x's automated cell partitioning for reliable, high-quality results. Built on 10x's proven Flex chemistry, the assay delivers exceptional sensitivity and sequencing efficiency in a scalable workflow. Its automation-compatible, plate-based multiplexing supports modular usage, enabling greater experimental flexibility and scale while reducing reagent waste - delivering more data at lower cost and extending single cell analysis to studies that previously relied on bulk methods.
"As we increase scalability and ease of use, researchers are unlocking more - more samples, more conditions, more insights - at a fraction of the previous cost. And as AI-driven approaches evolve, the need for high-quality biological data is only accelerating," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "This next generation of Flex represents a transformational step forward in enabling large scale, foundational and translational studies, as well as routine single cell use."
Early access customers have begun using new Flex across a range of discovery and translational research programs.
"Single cell technologies have transformed our understanding of human health and disease. However, traditional single cell multi-omics approaches have typically profiled only thousands of cells per experiment, making it difficult to scale or capture the complex dynamics that underpin our immune response to disease," said Peter Skene, Senior Director, High Resolution Immunology at the Allen Institute. "The new 384-plex Flex assay from 10x Genomics is a game changer - enabling the profiling of millions of cells at a fraction of the cost. By fixing cells for batching and ensuring compatibility with liquid-handling automation, we can now explore functional immune responses with unprecedented depth and precision."
"The next generation of the Flex assay delivers 10x's most streamlined and robust single cell profiling to date," said Stephen Christensen, Senior Principal Scientist, Immunology at Pfizer. "The ability to multiplex entire studies and process them in less time will be a powerful enabler for accelerating drug discovery and development."
New Flex is now available globally. For more information, visit 10xgenomics.com or contact your 10x Genomics representative.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended March 31, 2025 and 10-K for the fiscal year ended December 31, 2024 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-the-next-generation-of-chromium-flex-to-empower-scientists-to-massively-scale-single-cell-research-302597705.html
SOURCE 10x Genomics, Inc.
FAQ
What did 10x Genomics announce on October 29, 2025 about the Flex assay (TXG)?
How many samples and cells can the new 10x Flex assay (TXG) profile per week?
Will the new 10x Flex assay (TXG) work with lab automation and liquid handlers?
What research applications does the new 10x Flex (TXG) target?
How does 10x Genomics claim the new Flex assay affects cost and reagent use (TXG)?
